Regeneron publishes corporate presentation highlighting Q2 pipeline progress and product sales trends
REGN•Pipeline updates
- Pipeline focus included Otarmeni cleared by the FDA for genetic hearing loss, cemdisiran filings in generalized myasthenia gravis with an FDA decision expected in November 2026.
EYLEA sales trends
- EYLEA HD and EYLEA U.S. net product sales totaled USD 596 million, with EYLEA HD about 60% of the combined figure.
Q2 revenue, EPS and Dupixent sales
- Regeneron highlighted Q2 2026 revenue of USD 4.3 billion, non-GAAP EPS of USD 14.29.
- Dupixent collaboration showed Q2 global net sales of USD 6 billion, up 38% year over year, with more than 1,500,000 patients on therapy.
- Sanofi antibody development balance for Dupixent was fully reimbursed as of June 30, 2026, supporting a step-up in collaboration revenue in Q3.
